Athernal Bio
Targeted immunotherapies aim to stop blood cancers by treating high-risk clonal hematopoiesis before malignancy emerges.
~£700KGrant
ParticipantIU
Innovate UK
Activity from announced rounds
Activity in this selectionBiotech
Innovate UK is the innovation agency identified as a grant backer by Respiro Diagnostics and through its Investor Partnerships Programme by Adaptavate.
Recorded funding activity
Adaptavate develops lower-carbon building materials. Other recorded companies include Productive Machines’ CNC setup software and Athernal’s targeted therapies for high-risk blood conditions. Grant and investment-program participation must retain the instrument stated in each announcement.
Sources
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $5.9M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionRespiro Diagnostics
Develops breath-based diagnostic platform for lung cancer and respiratory diseases
£1MPre-Seed
Role not disclosedQuberTech
Develops sustainable natural rubber from engineered dandelions using controlled-environment biotech
£3.4MSeed
Role not disclosed